Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.
Damm F, Heuser M, Morgan M, Wagner K, Görlich K, Grosshennig A, Hamwi I, Thol F, Surdziel E, Fiedler W, Lübbert M, Kanz L, Reuter C, Heil G, Delwel R, Löwenberg B, Valk PJ, Krauter J, Ganser A. Damm F, et al. Among authors: gorlich k. Blood. 2011 Apr 28;117(17):4561-8. doi: 10.1182/blood-2010-08-303479. Epub 2011 Mar 3. Blood. 2011. PMID: 21372155 Free article.
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K, Damm F, Göhring G, Görlich K, Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar AA, Fiedler W, Kirchner HH, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A, Krauter J. Wagner K, et al. Among authors: gorlich k. J Clin Oncol. 2010 May 10;28(14):2356-64. doi: 10.1200/JCO.2009.27.6899. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368538
FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.
Wagner K, Damm F, Thol F, Göhring G, Görlich K, Heuser M, Schäfer I, Schlegelberger B, Heil G, Ganser A, Krauter J. Wagner K, et al. Among authors: gorlich k. Haematologica. 2011 May;96(5):681-6. doi: 10.3324/haematol.2010.034074. Epub 2011 Jan 17. Haematologica. 2011. PMID: 21242187 Free PMC article. Clinical Trial.
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
Thol F, Kade S, Schlarmann C, Löffeld P, Morgan M, Krauter J, Wlodarski MW, Kölking B, Wichmann M, Görlich K, Göhring G, Bug G, Ottmann O, Niemeyer CM, Hofmann WK, Schlegelberger B, Ganser A, Heuser M. Thol F, et al. Among authors: gorlich k. Blood. 2012 Apr 12;119(15):3578-84. doi: 10.1182/blood-2011-12-399337. Epub 2012 Mar 2. Blood. 2012. PMID: 22389253 Free article.
ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia.
Damm F, Wagner K, Görlich K, Morgan M, Thol F, Yun H, Delwel R, Valk PJM, Löwenberg B, Heuser M, Ganser A, Krauter J. Damm F, et al. Among authors: gorlich k. Br J Haematol. 2012 Jul;158(2):208-215. doi: 10.1111/j.1365-2141.2012.09144.x. Epub 2012 May 9. Br J Haematol. 2012. PMID: 22568493 Free article. Clinical Trial.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Görlich K, Wichmann M, Schwarzer A, Preller M, Thol F, Meyer J, Haemmerle R, Struys EA, Jansen EE, Modlich U, Li Z, Sly LM, Geffers R, Lindner R, Manstein DJ, Lehmann U, Krauter J, Ganser A, Heuser M. Chaturvedi A, et al. Among authors: gorlich k. Blood. 2013 Oct 17;122(16):2877-87. doi: 10.1182/blood-2013-03-491571. Epub 2013 Aug 16. Blood. 2013. PMID: 23954893 Free article.
Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening.
Sharma A, Jyotsana N, Lai CK, Chaturvedi A, Gabdoulline R, Görlich K, Murphy C, Blanchard JE, Ganser A, Brown E, Hassell JA, Humphries RK, Morgan M, Heuser M. Sharma A, et al. Among authors: gorlich k. Curr Cancer Drug Targets. 2016;16(9):818-828. doi: 10.2174/1568009616666160617103301. Curr Cancer Drug Targets. 2016. PMID: 27321378
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.
Chaturvedi A, Gupta C, Gabdoulline R, Borchert NM, Goparaju R, Kaulfuss S, Görlich K, Schottmann R, Othman B, Welzenbach J, Panknin O, Wagner M, Geffers R, Ganser A, Thol F, Jeffers M, Haegebarth A, Heuser M. Chaturvedi A, et al. Among authors: gorlich k. Haematologica. 2021 Feb 1;106(2):565-573. doi: 10.3324/haematol.2019.236992. Haematologica. 2021. PMID: 32241846 Free PMC article.
15 results